Company Overview and News

5
Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q1 2018 Update

2018-05-17 seekingalpha
Fairfax Financial’s largest five stakes are BlackBerry, Resolute Forest Products, Kennedy-Wilson, USG, and Intrepid Potash. They together account for ~85% of the US long assets.

2
SSW / Seaspan Corp. 6-K (Current Report of Foreign Issuer)

2018-05-11 sec.gov
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

 
Is iShares Emerging Markets Dividend ETF (DVYE) a Hot ETF Right Now?

2018-05-10 zacks
The iShares Emerging Markets Dividend ETF (DVYE - Free Report) made its debut on 02/23/2012, and is a smart beta exchange traded fund that provides broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.

1
SSW / Seaspan Corp. 424B3 (Prospectus)

2018-05-09 sec.gov
424B3 Filed Pursuant to Rule 424(b)(3) No: 333-224288 PROSPECTUS 1,986,449 Series D Preferred Shares

 
SSW / Seaspan Corp. 424B7 (Prospectus)

2018-05-09 sec.gov
424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-224288 PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus Dated May 8, 2018)

7
SSW / Seaspan Corp. F-3/A

2018-05-07 sec.gov
F-3/A Table of Contents As filed with the Securities and Exchange Commission on May 7, 2018 Registration Statement No. 333-224288

 
Seaspan Corporation: A Low-Risk 5.48% Yield-To-Maturity For One Year

2018-05-07 seekingalpha
Brief introduction of the company itself, the products of interest to us and how they compare to one another.

2
SSW / Seaspan Corp. 6-K (Current Report of Foreign Issuer)

2018-05-04 sec.gov
ssw-6k_20180331.htm UNITED STATES

6
SSW / Seaspan Corp. F-3/A

2018-05-03 sec.gov
F-3/A Table of Contents As filed with the Securities and Exchange Commission on May 3, 2018 Registration Statement No. 333-224288

 
Seaspan's (SSW) CEO Bing Chen on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Welcome to the Seaspan Corporation Conference Call to discuss the financial results for the quarter ended March 31, 2018. Hosting the call today are David Sokol, Chairman of Seaspan Corporation, Bing Chen, President and Chief Executive Officer; Peter Curtis, Executive Vice President and Chief Commercial and Technical Officer and David Spivak, Chief Financial Officer, and Ryan Courson, Senior Vice President, Corporate Development.

 
Seaspan Corporation 2018 Q1 - Results - Earnings Call Slides

2018-05-03 seekingalpha
The following slide deck was published by Seaspan Corporation in conjunction with their 2018 Q1 earnings call.

 
6 Short-Term Baby Bonds To Protect You From Interest Rate Risk - Part 1

2018-04-25 seekingalpha
In terms of increased political and interest rate risk, we chose 6 short-term baby bonds (with a maturity date in less than 6 years) to protect your portfolio.

 
SSW / Seaspan Corp. / Carlyle Group L.P. - SC 13D (Activist Investment)

2018-04-20 sec.gov
SC 13D United States Securities and Exchange Commission Washington, D.C. 20549

 
SSW / Seaspan Corp. / Carlyle Group L.P. - SC 13D (Activist Investment)

2018-04-20 sec.gov
SC 13D United States Securities and Exchange Commission Washington, D.C. 20549

 
SSW / Seaspan Corp. FORM 6-K (Current Report of Foreign Issuer)

2018-04-20 sec.gov
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: Y75638125